Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
Authors:
Open Access
- 12 March 2020
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 9 (1) , 117-133
Abstract
Introduction Sialorrhea is a common and debilitating symptom associated with neurological conditions, which can result in considerable physical and psychosocial complications. In Australia, management options are limited and further impeded by the lack of approved treatments. Whilst there is emerging evidence for the efficacy and tolerability of botulinum toxin (BoNT) for the treatment of sialorrhea in patients with neurological conditions, the cost-effectiveness of the treatment is yet to be established. Objectives To evaluate the cost-effectiveness of incobotulinumtoxinA for the treatment of chronic troublesome sialorrhea caused by various neurological conditions from the Australian healthcare perspective. Methods A Markov state transition model was developed to perform a cost-utility analysis comparing incobotulinumtoxinA with standard of care (SoC). The model consisted of a hypothetical cohort of patients transiting between three severity-based health states, defined according to the Drooling Severity and Frequency Scale (DSFS), in 16-weekly cycles over 5 years. All clinical and utility inputs were sourced from a single placebo-controlled randomised clinical trial. Only direct healthcare costs were considered, and potential indirect costs such as carer’s time and lost productivity were ignored. The primary outcome measure was the incremental cost per quality-adjusted life-year (QALY). Univariate and probabilistic sensitivity analyses were conducted. Results The model demonstrated that proportionally more patients spent time in less severe sialorrhea health states in the incobotulinumtoxinA arm. For example, over the 5-year period, patients receiving incobotulinumtoxinA were estimated to spend 1.6 years with minimal or no sialorrhea, while no patients achieved this level of improvement under SoC. IncobotulinumtoxinA was shown to have an incremental cost per QALY gained of A$23,445 when compared with SoC. Conclusions The quality of life (QoL) of patients with sialorrhea caused by neurological conditions was considerably compromised. IncobotulinumtoxinA was shown to successfully alleviate sialorrhea and it was demonstrated to be a cost-effective intervention when compared with SoC alone.Keywords
Funding Information
- Merz Pharmaceuticals
This publication has 38 references indexed in Scilit:
- Botulinum Toxin for the Treatment of SialorrheaOtolaryngology–Head and Neck Surgery, 2012
- Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double‐blind trialMovement Disorders, 2011
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010
- Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's diseaseMovement Disorders, 2009
- Sialorrhea in Parkinson's disease: A reviewMovement Disorders, 2007
- Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonismMovement Disorders, 2007
- Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled studyMovement Disorders, 2006
- Controlling sialorrhoea: a review of available treatment optionsExpert Opinion on Pharmacotherapy, 2005
- Salivary production in Parkinson's diseaseMovement Disorders, 2004
- Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonismMovement Disorders, 2003